Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Regeneron Pharmaceuticals Inc stake
total: 670
Viking Global Investors REGN trades
- Total transactions:
- 8
- New positions:
- 3
- Sold out:
- 3
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Regeneron Pharmaceuticals Inc (REGN) shares. To date, the estimated cost basis is nearly $634.23 for "buy" trades and estimated average "sell" price is $634.23. Viking Global Investors first purchased REGN in 2014 Q1, initially acquiring about 1.05M shares. Ole Andreas Halvorsen later completely sold out the position and invested in Regeneron Pharmaceuticals Inc again in 2025 Q1. Since the initial investment in Regeneron Pharmaceuticals Inc (REGN), Viking Global Investors has made 7 more transactions.
When did Ole Andreas Halvorsen sell Regeneron Pharmaceuticals Inc (REGN)?
Ole Andreas Halvorsen sold off the entire Regeneron Pharmaceuticals Inc (REGN) position in 2025 Q2.
When did Ole Andreas Halvorsen buy Regeneron Pharmaceuticals Inc (REGN)?
Ole Andreas Halvorsen first invested in Regeneron Pharmaceuticals Inc (REGN) in 2014 Q1 at the reported quarter-end price of $300.28 per share.
What's the cost basis of Viking Global Investors's REGN stake?
The estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) stake is around $634.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $634.23
- Weighted AVG sell price:
- $634.23
Ole Andreas Halvorsen's historical trades in Regeneron Pharmaceuticals Inc
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$634.23
|
|
-100% (-97,739)
|
-0.2%
|
|
2025 Q1
|
0.20%
|
97,739
|
$634.23
|
$61,989,006
|
new
|
+0.2%
|
|
2024 Q4
|
0.00%
|
0
|
$1,051.24
|
|
-100% (-49,870)
|
-0.19%
|
|
2024 Q3
|
0.19%
|
49,870
|
$1,051.24
|
$52,425,339
|
new
|
+0.19%
|
|
2014 Q4
|
0.00%
|
$360.52
|
-100% (-1,080,682)
|
|||
|
2014 Q3
|
1.56%
|
$360.52
|
-63.53% (-1,882,774)
|
|||
|
2014 Q2
|
3.65%
|
$282.47
|
+181.75% (+1,911,656)
|
|||
|
2014 Q1
|
1.32%
|
$300.28
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.